Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01735305

Acronym

OPT-CAD

Enrollment

14032

Registered

2012-11-28

Start date

2012-11-30

Completion date

2015-03-31

Last updated

2015-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Coronary Artery Disease, antiplatelet therapy

Brief summary

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Detailed description

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were at physician discretion.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. Clinical diagnosis of coronary heart disease 2. Age \>= 18 years old 3. receiving any antiplatelet agents 4. Informed written consent signed

Exclusion criteria

1. With severe disease and life expectancy for 6 months or less 2. Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.) 3. Taking part in an interventional clinical research

Design outcomes

Primary

Measure	Time frame	Description
Major adverse cardiac and cerebral events	12month	a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke

Secondary

Measure	Time frame	Description
Stent thrombosis	12 month	by BARC definition
rehospitalization	12 month	any rehospitalization for cardiac or noncardiac reasons
any bleeding events	12 month	by BARC definition
all cause death	12month	—
myocardial infarction	12 months	—
stroke	12 months	—
any revascularization	12 months	—
recurrent angina	12 month	—

Countries

China

Outcome results